Genetic profiling to inform people about their risk for dozens of diseases and traits comes with the assumption that identifying an increased risk could lead to preventive measures to reduce a person's risk for developing disease or to improve disease outcome. But little is known about the public's understanding and perceptions of such care, or what is really useful in day-to-day healthcare from the physician-patient perspective. We will present research that surveys the attitudes of early seekers of personalized genetic information by hearing from study participants themselves and a panel of experts covering the many aspects of this brave new world.

An ongoing collaborative study at the University of Pennsylvania School of Medicine and the Coriell Institute is probing the motivations of people who seek out this ultimately tailored information. The study is part of the Coriell Personalized Medicine Collaborative (CPMC), longitudinal research that involves participants giving a DNA sample and completing a series of medical history, family history, lifestyle, and medication questions. They then receive a risk assessment for common complex diseases, such as diabetes and heart disease, based on genetic risk factors as well as family history and lifestyle risk factors.  


Please join us for a writers’ roundtable to discuss these issues with study participants, and from a clinician, genetic counseling, and bioethics perspective.


Roundtable Participants

  • Dan Rader, MD, professor of Medicine and Pharmacology and director, Preventive Cardiovascular Medicine and Lipid Clinic at Penn, will discuss how genetic information can be used from a patient-physician perspective.
  • Art Caplan, PhD, director of the Center for Bioethics at Penn, will discuss how genetic information might be used, abused, or both.
  • Barbara Bernhardt, MS, CGC, genetic counselor and clinical associate professor of Medicine in Medical Genetics at Penn; co-investigator on the Penn study, will discuss study participants’ motivations for enrolling in the study and their attitudes toward their results.
  • Michael F. Christman, PhD, president and CEO, Coriell Institute and principal investigator, CPMC, will talk about the overall CPMC study. 
  • Study participants will talk about what motivated them to participate in the study; how they might use their genetic information in the future to change their behavior; who they might share it with; and concerns about sharing it.


Wednesday, May 19, 2010: 8:30am – 11:00am

Discussion begins at 8:45am. Coffee and light refreshments offered at the start of the roundtable.




Please register to attend in person by contacting Karen Kreeger at 215-349-5658 or Space is limited.

Media RSVPs for the webcast are also appreciated.


Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.